Herceptin Adjuvant Breast Cancer Sales Slow In First Quarter
This article was originally published in The Pink Sheet Daily
Genentech eyes additional opportunities for trastuzumab in adjuvant setting in node-positive, hormone receptor-positive breast cancer patients.
You may also be interested in...
Rapid uptake seen in 2006 is likely to level off this year as patients transition to lower dose frequency, according to the firm.
The average cost per course of therapy in the adjuvant indication is significantly more than for metastatic cancer.
Genentech is planning a supplemental BLA for Herceptin (trastuzumab) for adjuvant treatment of early stage breast cancer. Much-lauded Phase III data at American Society of Clinical Oncology meeting show significant reduction in disease recurrence and overall survival improvement of 49% at four years.